Shares of OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) were down 6.2% on Wednesday . The company traded as low as $10.01 and last traded at $10.17, with a volume of 148,672 shares traded. The stock had previously closed at $10.84.

A number of analysts have recently weighed in on OMED shares. Zacks Investment Research downgraded shares of OncoMed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 16th. Mizuho upped their price objective on shares of OncoMed Pharmaceuticals from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 26th. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price objective on shares of OncoMed Pharmaceuticals in a research report on Thursday, July 14th. Leerink Swann upped their price objective on shares of OncoMed Pharmaceuticals from $11.00 to $13.00 and gave the stock a “market perform” rating in a research report on Thursday, May 5th. Finally, Jefferies Group upped their price objective on shares of OncoMed Pharmaceuticals from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, August 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $19.29.

The firm’s market capitalization is $306.40 million. The stock’s 50-day moving average is $11.74 and its 200 day moving average is $11.55.

OncoMed Pharmaceuticals (NASDAQ:OMED) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.81) by $0.10. During the same period last year, the firm earned ($0.72) EPS. The firm had revenue of $6.67 million for the quarter, compared to analysts’ expectations of $8.09 million. The firm’s quarterly revenue was up 42.2% on a year-over-year basis. On average, equities analysts predict that OncoMed Pharmaceuticals Inc. will post ($3.39) earnings per share for the current year.

An institutional investor recently bought a new position in OncoMed Pharmaceuticals stock. Jennison Associates LLC bought a new stake in OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 89,546 shares of the biopharmaceutical company’s stock, valued at approximately $2,018,000. Jennison Associates LLC owned 0.30% of OncoMed Pharmaceuticals at the end of the most recent quarter.

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.